A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
Study Details
Study Description
Brief Summary
Dose escalation and expansion phase I/IIa clinical study of recombinant humanized type II CD20 monoclonal antibody MIL62 injection combined with a novel selective Bruton Tyrosine Kinase(BTK) inhibitor Orelabrutinib in the treatment of recurrent/refractory CD20+B cell lymphoma
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Single Arm
|
Drug: Orelabrutinib
BTK inhibitor Orelabrutinib low dose or high dose; Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.
Drug: Recombinant humanized monoclonal antibody MIL62 injection
Recombinant humanized monoclonal antibody MIL62 injection, 800mg or1000mg each time, Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.
|
Outcome Measures
Primary Outcome Measures
- Dose limiting toxicity (DLT)(Dose escalation phase) [At the end of Cycle 1 (each cycle is 28 days)]
Safety observation indicator
- Maximum tolerated dose (MTD) (Dose escalation phase) [At the end of Cycle 1 (each cycle is 28 days)]
Safety observation indicator
- Recommended dose for phase 2 trials of two-drug combinations (RP2D) (Dose escalation phase) [At the end of Cycle 1 (each cycle is 28 days)]
Safety observation indicator
- objective remission rate(ORR) (Dose expansion phase) [At the end of Cycle 30 (each cycle is 28 days)]
Efficacy observation indicator
Secondary Outcome Measures
- objective remission rate(ORR) [At the end of Cycle 30 (each cycle is 28 days)]
Efficacy observation indicator
- Area under the plasma concentration vs time curve(AUC) [At the end of Cycle 6 (each cycle is 28 days)]
pharmacokinetic parameter of MIL62 combined with Orelabrutinib in the treatment
- Apparent half-life for designated elimination phases (t½) [At the end of Cycle 6 (each cycle is 28 days)]
pharmacokinetic parameter of MIL62 combined with Orelabrutinib in the treatment
- The peak plasma concentration (Cmax) [At the end of Cycle 6 (each cycle is 28 days)]
pharmacokinetic parameter of MIL62 combined with Orelabrutinib in the treatment
- Duration of remission(DOR) [3 years after first treatment]
Efficacy observation indicator
- Progression-free survival(PFS) in the treatment of R/R CD20+B cell lymphoma [3 years after first treatment]
Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of relapsed/refractory CD20+B cell lymphoma with 3-year progression-free survival
- overall survival(OS) in the treatment of R/R CD20+B cell lymphoma [3 years after first treatment]
Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of recurrent/refractory CD20+B cell lymphoma with 3-year overall survival
- Duration of remission(DOR) in the treatment of R/R NHL [3 years after first treatment]
Preliminary evaluation of remission duration of MIL62 combined with Orelabrutinib in the treatment of Recurrent/refractory Non Hodgkin Lymphoma
- Progression-free survival(PFS) in the treatment of R/R NHL [3 years after first treatment]
Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of Recurrent/refractory Non Hodgkin Lymphoma with 3-year progression-free survival
- overall survival(OS) in the treatment of R/R NHL [3 years after first treatment]
Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of Recurrent/refractory Non Hodgkin Lymphoma with 3-year overall survival
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥18 years, gender not limited
-
Dose escalation phase: Histologically confirmed CD20 positive B-cell non-Hodgkin's lymphoma; Expansion stage: R/R NHL Or histologically diagnosed CD20 positive chronic lymphocytic leukemia/small lymphocytic lymphoma;
-
Dose escalation phase ：Patients who have received at least one treatment regimen Expansion stage：Patients who have received at least one to four treatment regimens with at least one regimen containing rituximab;
-
Eastern cancer collaboration group(ECOG) physical status score: 0-2
-
Laboratory tests performed within 7 days prior to the first acceptance of the study drug met the protocol criteria.
-
Expected survival ≥6 months
-
Sign a written informed consent.
Exclusion Criteria:
-
Expansion stage: DLBCL transformed from follicular lymphoma, DLBCL with follicular lymphoma, and lymphomas with primary or central nervous system involvement.
-
Received any of the anti-tumor treatments(note in the protocol) before the first study drug.
-
Previous use of any anticancer vaccine.
-
Patients who had received hematopoietic stem cell transplantation within 3 months before the first administration
-
Patients scheduled for major surgery within 28 days prior to initial administration or during the expected study period.
-
Patients who Is participating in other clinical trials or first administration less than 28 days after the end of the previous clinical trial.
-
Receiving prednisone treatment or other corticosteroid treatment with the same dose as prednisone ;Patients who require warfarin or an equivalent vitamin K antagonist;
-
During the study period, drugs with moderate or severe inhibition or strong induction of cytochrome CYP3A4 were taken together;
-
Subject has a history of any of the diseases note in the protocol;
-
Patients with infections;
-
Impact testing scheme compliance or other serious results explain the poor control of the merger of the disease(note in the protocol);
-
Toxicity of any previous anticancer treatment has not recovered to ≤1, except for hair loss;
-
A history of severe allergic reactions to humanized monoclonal antibodies or known allergies to any component of Orelabrutinib or MIL62;
-
Inability to swallow research drugs, or the presence of conditions that significantly affect gastrointestinal function;
-
Hepatitis b surface antigen (HBsAg) and/or hepatitis b core antibody (HBcAb) are positive ; Hepatitis c virus (HCV) antibody positive and HCV RNA positive patients; Human immunodeficiency virus (HIV) serum response was positive;
-
Pregnant and lactating women; For women of childbearing age who have not undergone sterilization surgery: do not agree to use appropriate methods of contraception;
-
For men not undergoing sterilization: do not agree to use the barrier method of contraception;
-
Other circumstances considered inappropriate for the study by the investigator.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The First Affiliated Hospital of Bengbu Medical College | Bengbu | Anhui | China | 100000 |
| 2 | Beijing Hospital | Beijing | Beijing | China | 100000 |
| 3 | Beijing Shijitan hospital, capital medical university | Beijing | Beijing | China | 100000 |
| 4 | Cancer hospital, Chinese academy of medical sciences | Beijing | Beijing | China | 100000 |
| 5 | Affiliated Hospital of Hebei University | Baoding | Hebei | China | 100000 |
| 6 | Henan Tumor Hospital | Zhengzhou | Henan | China | 100000 |
| 7 | Hunan Cancer Hospital | Changsha | Hunan | China | 100000 |
| 8 | First Affiliated Hospital of Soochow University | Suzhou | Jiangsu | China | 100000 |
| 9 | The First Hospital of Jilin University | Changchun | Jilin | China | 100000 |
| 10 | Tianjin People's Hospital | Tianjin | Tianjin | China | 100000 |
Sponsors and Collaborators
- Beijing InnoCare Pharma Tech Co., Ltd.
Investigators
- Principal Investigator: Yuankai Shi, PhD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MIL62-CT03